Last reviewed · How we verify

Micardis plus 80/12.5 — Competitive Intelligence Brief

Micardis plus 80/12.5 (Micardis plus 80/12.5) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker + thiazide diuretic combination. Area: Cardiovascular.

marketed Angiotensin II receptor blocker + thiazide diuretic combination AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Micardis plus 80/12.5 (Micardis plus 80/12.5) — Heart Care Foundation. Micardis Plus combines telmisartan (an angiotensin II receptor blocker) with hydrochlorothiazide (a thiazide diuretic) to lower blood pressure through dual mechanisms of vasodilation and sodium/fluid reduction.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Micardis plus 80/12.5 TARGET Micardis plus 80/12.5 Heart Care Foundation marketed Angiotensin II receptor blocker + thiazide diuretic combination AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter
losartan and HCTZ losartan and HCTZ InVasc Therapeutics, Inc. marketed Angiotensin II receptor blocker + thiazide diuretic combination AT1 receptor (losartan); sodium-chloride cotransporter (HCTZ)
olmesartan medoxomil + hydrochlorothiazide, if necessary olmesartan medoxomil + hydrochlorothiazide, if necessary Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company marketed Angiotensin II receptor blocker + thiazide diuretic combination AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
Candesartan plus Hydrochlorothiazide Candesartan plus Hydrochlorothiazide Novartis phase 3 Angiotensin II receptor blocker + Thiazide diuretic combination AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
Candesartan+HCTZ - Phase 1 Candesartan+HCTZ - Phase 1 Novartis phase 3 Angiotensin II receptor blocker + thiazide diuretic combination AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
Fimasartan; Hydrochlorothiazide Fimasartan; Hydrochlorothiazide Stendhal Americas, S.A. phase 3 Angiotensin II receptor blocker + thiazide diuretic combination AT1 receptor (fimasartan); sodium-chloride cotransporter (hydrochlorothiazide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker + thiazide diuretic combination class)

  1. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
  2. Heart Care Foundation · 1 drug in this class
  3. InVasc Therapeutics, Inc. · 1 drug in this class
  4. Novartis · 1 drug in this class
  5. Stendhal Americas, S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Micardis plus 80/12.5 — Competitive Intelligence Brief. https://druglandscape.com/ci/micardis-plus-80-12-5. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: